Design, Synthesis, and Biological Evaluation of Eukaryotic Initiation Factor 2B (eIF2B) Activators
ChemMedChem · 03.06.2024 · 19 (11)
DOI: 10.1002/cmdc.202300716 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 26.03.2024. Verfasst von Yifeng Pei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing, 210009, PR China. Hauptthemen laut MEDLINE: Activating Transcription Factor 4, Drug Design, Eukaryotic Initiation Factor-2B. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Lingang Laboratory.
Abstract (Originalsprache)
The eukaryotic initiation factor 2B (eIF2B) is a key regulator in protein‐regulated signaling pathways and is closely related to the function of the central nervous system. Modulating eIF2B could retard the process of neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and vanishing white matter disease (VWM) et al. Here, we designed and synthesized a series of novel eIF2B activators containing oxadiazole fragments. The activating effects of compounds on eIF2B were investigated through testing the inhibition of ATF4 expression. Of all the targeted compounds, compounds 21 and 29 exhibited potent inhibition on ATF4 expression with IC 50 values of 32.43 nM and 47.71 nM, respectively, which were stronger than that of ISRIB (IC 50 =67.90 nM). ATF4 mRNA assay showed that these two compounds could restore ATF4 mRNA to normal levels in thapsigargin‐stimulated HeLa cells. Protein Translation assay showed that both compounds were effective in restoring protein synthesis. Compound potency assay showed that both compounds had similar potency to ISRIB with EC 50 values of 5.844 and 37.70 nM. Cytotoxicity assay revealed that compounds 21 and 29 had low toxicity and were worth further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Discovery, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing, 210009, PR China.
- New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, China.
- Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
ORCID-Profile: Huibin Zhang
Förderung
- Lingang Laboratory
Zitieren
APA
Pei, Y., Liu, S., Wang, L., Chen, C., Hu, M., Xue, Y., Guan, D., Xie, L., Liao, H., Zhou, J., & Zhang, H. (2024). Design, Synthesis, and Biological Evaluation of Eukaryotic Initiation Factor 2B (eIF2B) Activators. ChemMedChem, 19(11). https://doi.org/10.1002/cmdc.202300716
Vancouver
Pei Y, Liu S, Wang L, Chen C, Hu M, Xue Y, et al. Design, Synthesis, and Biological Evaluation of Eukaryotic Initiation Factor 2B (eIF2B) Activators. ChemMedChem. 2024;19(11). doi:10.1002/cmdc.202300716
BibTeX
@article{Pei2024,
author = {Pei, Yifeng and Liu, Sentao and Wang, Lixun and Chen, Chao and Hu, Mengqiu and Xue, Yi and Guan, Dezhong and Xie, Lingfeng and Liao, Hong and Zhou, Jinpei and Zhang, Huibin},
title = {Design, Synthesis, and Biological Evaluation of Eukaryotic Initiation Factor 2B (eIF2B) Activators},
journal = {ChemMedChem},
year = {2024},
volume = {19},
number = {11},
doi = {10.1002/cmdc.202300716}
}
EUVIMED